Skip to main content

Recombinant Human IGFBP-5 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 875-B5

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
875-B5-025

Key Product Details

Source

NS0

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human IGFBP-5 protein
Leu21-Glu272, with an N-terminal Met

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Glu28 (Major) & Met-Leu21 (Minor)

Predicted Molecular Mass

28-29 kDa

SDS-PAGE

35-37 kDa, reducing conditions

Activity

Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF-7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083.
The ED50 for this effect is 0.5-1.5 µg/mL in the presence of 14 ng/mL rhIGF-II.

Formulation, Preparation and Storage

875-B5
Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGFBP-5

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-transitional modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Human IGFBP-5 cDNA encodes a 272 amino acid (aa) residue precursor protein with a putative 20 aa residue signal peptide that is processed to generate the 252 aa residue mature protein that is post-translationally modified by O-glycosylations and serine phosphorylations. IGFBP-5 is expressed by fibroblasts, myoblasts and osteoblasts, making it the predominant IGFBP found in bone extracts. IGFBP-5 has a strong affinity for hydroxyapatite, allowing it to bind to bone cells. When bound to extracellular matrix, IGFBP-5 is protected from proteolysis and potentiates IGF activity, but when it is soluble, IGFBP-5 is cleaved to a biologically inactive 21 kDa fragment.

References

  1. Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
  2. Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.

Long Name

Insulin-like Growth Factor Binding Protein 5

Alternate Names

IGFBP5

Entrez Gene IDs

3488 (Human); 16011 (Mouse)

Gene Symbol

IGFBP5

UniProt

Additional IGFBP-5 Products

Product Documents for Recombinant Human IGFBP-5 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human IGFBP-5 Protein, CF

For research use only

Loading...
Loading...
Loading...
Loading...